Specific changes in beta2-adrenoceptor trafficking kinetics and intracellular sorting during downregulation

Eur J Pharmacol. 1999 Mar 12;369(1):113-23. doi: 10.1016/s0014-2999(99)00055-2.

Abstract

Agonist-activated beta2-adrenoceptors rapidly internalize and then recycle to the cell surface, however chronic agonist eventually causes receptor downregulation. To characterize beta2-adrenoceptor trafficking kinetics and intracellular sorting during downregulation, human embryonic kidney cells expressing epitope-tagged receptors were examined by radioligand binding with (+/-)-[3H]4-(3-tertiarybutylamino-2-hydroxypropoxy)-benzimidazole- 2-on hydrochloride ([3H]CGP12177) and immunofluorescence microscopy. The first-order receptor recycling rate constant declined after 18 h of agonist compared with 15 min (0.05 min(-1) vs. 0.12 min(-1)), thus increasing the intracellular transit time (20.0 min vs. 8.3 min). There was also a reduction in the rate of receptor endocytosis and a decline in the total number of receptors. Although the intracellular receptor fraction did not increase between 15 min and 18 h of agonist, some receptors moved irreversibly into a protease-containing compartment while retaining radioligand binding activity. Our results indicate that beta2-adrenoceptor downregulation is associated principally with an increased intracellular transit time during recycling. This could promote the diversion of receptors into protease-containing compartments, where there is an irreversible commitment to downregulation prior to loss of radioligand binding activity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Antagonists / metabolism
  • Adrenergic beta-Antagonists / pharmacology
  • Biological Transport
  • Cell Line
  • Down-Regulation*
  • Endocytosis / drug effects
  • Endocytosis / physiology
  • Humans
  • Isoproterenol / pharmacology
  • Kinetics
  • Propanolamines / metabolism
  • Propanolamines / pharmacology
  • Protease Inhibitors / pharmacology
  • Radioligand Assay
  • Receptors, Adrenergic, beta-2 / drug effects
  • Receptors, Adrenergic, beta-2 / physiology*
  • Sensitivity and Specificity
  • Time Factors
  • Tritium

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Propanolamines
  • Protease Inhibitors
  • Receptors, Adrenergic, beta-2
  • Tritium
  • Isoproterenol
  • CGP 12177